The management of opiate use disorders in France: results of an observational survey of general practitioners

Addiction Science & Clinical Practice

Pierre Poloméni¹  Claude Bronner²  Fréderic Fry⁵  Bruno Ravoninjatovo³  Mélina Fatseas⁴ 

[1] Hôpitaux Universitaires Paris Seine St Denis, Site René Muret, Avenue du Dr Schaeffner, Sevran 93270, France

[2] 2 rue de Haslach, Strasbourg, 67200, France

[3] 151 Bis rue de Courcelles, Reims, 51100, France

[4] Laboratoire de psychiatrie, Département d’addictologie, Centre hospitalier Charles Perrens, 146 bis, rue Léo Saignat, Bordeaux 33076, France

[5] CSAPA Dune, Parvis de la préfecture, Immeuble les Oreades, Cergy, 95000, France

关键词: Opioid-agonist management;    Opioid-agonist treatment;    Heroin;    Opiates;    Substance use disorders;    Specialists;    General practitioners;   

Others  :  1220290
DOI  :  10.1186/s13722-015-0037-2

 received in 2014-01-19, accepted in 2015-06-18,  发布年份 2015

【 摘 要 】

Background

When opioid-agonist treatments were approved in France in 1995, opiate use disorders began to be managed and treated by general practitioners (GPs), who have since then been encouraged to treat substance use disorders (SUDs) for heroin and other illegal substances. The objective of this study was to describe rates of: 1) SUDs in general practices in France; 2) characteristics of GPs treating SUDs; and 3) clinical practices surrounding SUDs. To place these data in the context of SUD treatment, we also gathered information from practicing SUD specialists.

Methods

Between December 2011 and January 2012, a nationally representative sample of GPs and SUD specialists were interviewed by phone, using a 12-item questionnaire that covered number of SUD patients, types of SUDs, and treatments. Data collected were confidential, and analysis was blinded with regard to physician identity.

Results

Forty-four percent of GPs and 68 % of specialists were included in the analysis. The mean number of patients estimated to have been seen at least once in the previous year was 3036 for GPs and 920 for specialists. Ninety-six percent of GPs reported having patients with SUDs. Tobacco, alcohol, and psychoactive drugs were the SUDs most frequently encountered by GPs, whereas tobacco, alcohol, heroin, and cannabis were most frequently encountered by specialists. Forty-three percent of GPs saw at least one patient with a heroin use disorder (HUD), and 82 % of GPs treating patients with HUDs had prescribed an opioid-agonist treatment during the previous 12 months.

Conclusions

The results of this study suggest that a large number of GPs now treat patients with opiate use disorders and that doctors appear to be convinced of the benefits of opioid-agonist therapy and have overcome their initial concerns. This represents a significant change in practice patterns since the introduction of opioid-agonist treatments in France.

【 授权许可】

   
2015 Poloméni et al.

【 图 表 】

Fig. 1.

Fig. 2.

【 参考文献 】

• [1]Duburcq A, Charpak Y, Blin P, Madec L. Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex). Rev Epidemiol Sante Publique. 2000; 48:363-73.
• [2]Gatignol C. Opiate replacement therapy in France. Ann Pharm Fr. 2009; 67:360-4.
• [3]Observatoire français des drogues et des toxicomanies: Drogues Chiffres Clés. 4e Ed. http://www.ofdt.fr/BDD/publications/docs/dcc2012.pdf. 2012: Accessed October 17, 2014.
• [4]Costes J-M, Vaissade L, Colasante E, Palle C, Legleye S, Janssen E, et al. Prévalence de l’usage problématique de drogues en France - estimations 2006. http://www.ofdt.fr/BDD/publications/docs/epfxjcp6.pdf. 2009: Accessed October 17, 2014.
• [5]European Monitoring Centre for Drugs and Drug Addiction: 2011 Annual report on the state of the drugs problem in Europe. http://www.emcdda.europa.eu/publications/annual-report/2011. 2011: Accessed October 17, 2014.
• [6]Guignard R, Beck F, Obradovic I. Prise en charge des addictions par les médecins généralistes. Baromètre santé médecins généralistes 2009. Saint Denis. 2011.177-201.
• [7]Agence nationale de sécurité du médicament et des produits de santé: Commission nationale des stupéfiants et des psychotropes. Compte-rendu de la 86ième réunion du 15 décembre 2009. http://ansm.sante.fr/var/ansm_site/storage/original/application/782c00f81619946fdb54bad8ee73b745.pdf. 2010: Accessed October 2014.
• [8]Boireau L. Les difficultés de la substitution aux opiacés en médecine générale : Etat des lieux dans le département de la Loire en 2009 et étude qualitative : Thèse de Médecine Générale, soutenue le 8/11/2010. Le Flyer. 2011; 43:4-9.
• [9]Observatoire français des drogues et des toxicomanies: Substitution aux opiacés en France. Synthèse des informations disponibles de 1996 à 2001 en France. http://www.ofdt.fr/BDD/publications/docs/epfxofj6.pdf. 2003: Accessed October 17, 2014.
• [10]Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007; 9:358-64.
• [11]Michel L. Opioid substitution therapy in France: a physician’s overview. Ann Pharm Fr. 2009; 67:369-73.
• [12]Observatoire français des drogues et des toxicomanies: 2012 National report (2011 data) to the EMCDDA by the Reitox National Focal Point France. New development, trends and in-depth information on selected issues. [http://www.emcdda.europa.eu/attachements.cfm/att_213784_EN_Austria_NR2012.pdf]. 2012: Accessed October 17, 2014.
• [13]Carpentier J. La toxicomanie à l’héroïne en médecine générale. Ellipses, Paris; 1993.
• [14]Charpak Y, Nory F, Barbot J. Management of drug addicts (heroin addicts) by general practitioners. Rev Epidemiol Publique. 1994; 42:224-34.
• [15]Guichard A, Lert F, Brodeur JM, Richard L. Buprenorphine substitution treatment in France: drug users’ views of the doctor-user relationship. Soc Sci Med. 2007; 64:2578-93.
• [16]Di Patrizio P, Houille S, Schwan R, Boivin JM. Buprenorphin and benzodiazepines, an association with high risk. Reality of co-prescriptions by the general practitioners. Rev Prat. 2010; 60:29-34.
• [17]Gordon AJ, Kunins HV, Rastegar DA, Tetrault JM, Walley AY. Update in addiction medicine for the generalist. J Gen Intern Med. 2011; 26:77-82.
• [18]Plancke L, Lose S, Amariei A, Benoît E, Chantelou M-L. Les traitements de substitution aux opiacés en médecine de ville dans le Nord - Pas-de-Calais. Lille: Granitea Nord-Pas-de-Calais. http://www.federationaddiction.fr/wp-content/uploads/2012/02/Rapport_tso_npdc-dec2010.pdf. 2010: Accessed October 17, 2014.
• [19]Moatti JP, Souville M, Escaffre N, Obadia Y. French general practitioners’ attitudes toward maintenance drug abuse treatment with buprenorphine. Addiction. 1998; 93:1567-75.
• [20]Cadet-Taïrou A, Cholley D. Approche régionale de la substitution aux opiacés (1999–2002) - Pratiques et disparités régionales. http://www.ofdt.fr/BDD/publications/docs/epfxack6.pdf]. 2004: Accessed October 17, 2014.
• [21]Strang J, Sheridan J, Hunt C, Kerr B, Gerada C, Pringle M. The prescribing of methadone and other opioids to addicts: national survey of GPs in England and Wales. Br J Gen Pract. 2005; 55:444-51.
• [22]Longman C, Temple-Smith M, Gilchrist G, Lintzeris N. Reluctant to train, reluctant to prescribe: barriers to general practitioner prescribing of opioid substitution therapy. Aust J Prim Health. 2012; 18:346-51.
• [23]Schulte B, Schmidt CS, Kuhnigk O, Schafer I, Fischer B, Wedemeyer H et al.. Structural barriers in the context of opiate substitution treatment in Germany—a survey among physicians in primary care. Subst Abuse Treat Prev Policy. 2013; 8:26. BioMed Central Full Text
• [24]Stover H. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2011; 17:44-54.
• [25]Grand-Filaire A, Grand A. Les médecins généralistes face aux conduites toxicomaniaques. Santé Publique. 1993; 2:73-81.
• [26]De Ducla M, Gagnon A, Mucchielli A, Robinet S, Vellay A. Follow-up of opioid addicts treated with high-dose buprenorphine in a health care network. National retrospective study. Experience of French general physicians. Ann Med Interne. 2000; 151 Suppl A:A27-32.
• [27]Touzeau D, Courty P. Opiates, harm reduction and polysubstance abuse. Presse Med. 2012; 41:1192-200.
• [28]Chossegros P. Management of drug addiction in France (a short history). Gastroenterol Clin Biol. 2007; 31:4S44-50.